Products for Research Use Only

Piribedil (Standard)

CAT: 0804-HY-12707R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12707R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Piribedil (Standard) is the analytical standard of Piribedil. This product is intended for research and analytical applications. Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM) . Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers[1][2][3][4].
CAS Number
3605-01-4
UNSPSC
12352005
Target
Adrenergic Receptor; Dopamine Receptor; Histone Methyltransferase; Reference Standards
Type
Reference Standards
Related Pathways
Epigenetics; GPCR/G Protein; Neuronal Signaling; Others
Field of Research
Cancer; Endocrinology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/piribedil-standard.html
Smiles
C1(N2CCN(CC3=CC=C(OCO4)C4=C3)CC2)=NC=CC=N1
Molecular Formula
C16H18N4O2
Molecular Weight
298.34
References & Citations
[1]Sweet RD, et al. Piribedil, a dopamine agonist, in Parkinson's disease. Clin Pharmacol Ther. 1974 Dec;16 (6) :1077-82. |[2]Gerlach M, et al. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α (2) adrenergic mechanisms. J Neural Transm (Vienna) . 2013 Jan;120 (1) :31-6. |[3]Smith LA, Tet al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002 Sep;17 (5) :887-901.|[4]Xiong Zhang, et al. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. Cancer Lett. 2018 Sep 1;431:150-160.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Popular Products